Oncology Central

Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer

0

With the advent of new drugs and therapeutic combinations for metastatic colorectal cancer, the prognosis for this often incurable disease is improving. In addition to traditional cytotoxic chemotherapeutics, targeted biologic therapies, such as cetuximab, panitumumab, bevacizumab, aflibercept and regorafenib, are significantly impacting the treatment of this disease. Recent investigations have focused on determination of the optimal usage of these biologic therapies, but many controversies still exist.

To view restricted content, please:
Share:

Leave A Comment